A phase III trial of the Herceptin biosimilar ALT-02
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 28 Apr 2017 New trial record
- 20 Apr 2017 This trial is expected to begin in 2017, according to an Alteogen media release.